These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33714907)

  • 1. Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients.
    Altieri M; Sérée O; Lobbedez T; Segol P; Abergel A; Blaizot X; Boillot O; Boudjema K; Coilly A; Conti F; Chazouillères O; Debette-Gratien M; Dharancy S; Durand F; Duvoux C; Francoz C; Gugenheim J; Hardwigsen J; Houssel-Debry P; Kamar N; Latournerie M; Lebray P; Leroy V; Neau-Cransac M; Pageaux GP; Radenne S; Salamé E; Saliba F; Samuel D; Vanlemmens C; Besch C; Launoy G; Dumortier J
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101514. PubMed ID: 33714907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longterm Risk of Solid Organ De Novo Malignancies After Liver Transplantation: A French National Study on 11,226 Patients.
    Sérée O; Altieri M; Guillaume E; De Mil R; Lobbedez T; Robinson P; Segol P; Salamé E; Abergel A; Boillot O; Conti F; Chazouillères O; Debette-Gratien M; Debray D; Hery G; Dharancy S; Durand F; Duvoux C; Francoz C; Gugenheim J; Hardwigsen J; Houssel-Debry P; Jacquemin E; Kamar N; Latournerie M; Lebray P; Leroy V; Mazzola A; Neau-Cransac M; Pageaux GP; Radenne S; Saliba F; Samuel D; Vanlemmens C; Woehl-Jaegle ML; Launoy G; Dumortier J
    Liver Transpl; 2018 Oct; 24(10):1425-1436. PubMed ID: 30021061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis.
    Mouchli MA; Singh S; Loftus EV; Boardman L; Talwalkar J; Rosen CB; Heimbach JK; Wiesner RH; Hasan B; Poterucha JJ; Kymberly WD
    Transplantation; 2017 Aug; 101(8):1859-1866. PubMed ID: 28272287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender, Race and Disease Etiology Predict De Novo Malignancy Risk After Liver Transplantation: Insights for Future Individualized Cancer Screening Guidance.
    Bhat M; Mara K; Dierkhising R; Watt KD
    Transplantation; 2019 Jan; 103(1):91-100. PubMed ID: 29377876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive regimen and risk for de novo malignancies after liver transplantation for alcoholic liver disease.
    Dumortier J; Maucort-Boulch D; Poinsot D; Thimonier E; Chambon-Augoyard C; Ducroux E; Vallin M; Walter T; Robinson P; Guillaud O; Boillot O
    Clin Res Hepatol Gastroenterol; 2018 Oct; 42(5):427-435. PubMed ID: 29861393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation - a multicenter cohort study.
    Shalaby S; Taborelli M; Zanetto A; Ferrarese A; D'Arcangelo F; Gambato M; Senzolo M; Russo FP; Germani G; Boccagni P; Ettorre GM; Baccarani U; Lauro A; Galatioto L; Rendina M; Petrara R; De Rossi A; Nudo F; Toti L; Fantola G; Vennarecci G; Risaliti A; Pinna AD; Gruttadauria S; Di Leo A; Rossi M; Tisone G; Zamboni F; Cillo U; Piselli P; Serraino D; Burra P;
    Transpl Int; 2021 Apr; 34(4):743-753. PubMed ID: 33492715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Significance of De Novo Malignancy After Liver Transplant: A Single-Center Study.
    Kim S; Rovgaliyev B; Lee JM; Lee KW; Hong SK; Cho JH; Yoon KC; Yi NJ; Suh KS
    Transplant Proc; 2021; 53(1):200-206. PubMed ID: 32409224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.
    Mouchli MA; Singh S; Boardman L; Bruining DH; Lightner AL; Rosen CB; Heimbach JK; Hasan B; Poterucha JJ; Watt KD; Kane SV; Raffals LE; Loftus EV
    Inflamm Bowel Dis; 2018 Apr; 24(5):1074-1081. PubMed ID: 29522202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De Novo Malignancy After Living Donor Liver Transplantation: A Large Volume Experience.
    Tiwari A; Saigal S; Choudhary NS; Saha S; Rastogi A; Bhangui P; Saraf N; Srinivasan T; Yadav SK; Gautam D; Nundy S; Soin AS
    J Clin Exp Hepatol; 2020; 10(5):448-452. PubMed ID: 33029053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence and risk factors of de novo skin cancer in the liver transplant recipients.
    Modaresi Esfeh J; Hanouneh IA; Dalal D; Tabba A; Lopez R; Pagadala M; Eghtesad B; Zein NN
    Int J Organ Transplant Med; 2012; 3(4):157-63. PubMed ID: 25013641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
    Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
    Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery.
    Lin C; Wu J; Ding S; Goh C; Andriani L; Lu S; Shen K; Zhu L
    J Natl Compr Canc Netw; 2019 Dec; 17(12):1521-1528. PubMed ID: 31805535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan.
    Yeh CC; Khan A; Muo CH; Yang HR; Li PC; Chang CH; Chen TL; Jeng LB; Liao CC
    Exp Clin Transplant; 2020 Apr; 18(2):224-233. PubMed ID: 32133940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival after the diagnosis of de novo malignancy in liver transplant recipients.
    Taborelli M; Piselli P; Ettorre GM; Baccarani U; Burra P; Lauro A; Galatioto L; Rendina M; Shalaby S; Petrara R; Nudo F; Toti L; Fantola G; Cimaglia C; Agresta A; Vennarecci G; Pinna AD; Gruttadauria S; Risaliti A; Di Leo A; Rossi M; Tisone G; Zamboni F; Serraino D;
    Int J Cancer; 2019 Jan; 144(2):232-239. PubMed ID: 30091809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term probability of and mortality from de novo malignancy after liver transplantation.
    Watt KD; Pedersen RA; Kremers WK; Heimbach JK; Sanchez W; Gores GJ
    Gastroenterology; 2009 Dec; 137(6):2010-7. PubMed ID: 19766646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of de novo cancer in liver transplant recipients.
    Riis TH; Møller DL; Høgh J; Knudsen AD; Rostved AA; Akdag D; Kirkby N; Lassen U; Rasmussen A; Hillingsø JG; Pommergaard HC
    APMIS; 2023 Apr; 131(4):135-141. PubMed ID: 36680559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo malignancy post-liver transplantation: a single center, population controlled study.
    Chatrath H; Berman K; Vuppalanchi R; Slaven J; Kwo P; Tector AJ; Chalasani N; Ghabril M
    Clin Transplant; 2013; 27(4):582-90. PubMed ID: 23808800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database.
    Zhou J; Hu Z; Zhang Q; Li Z; Xiang J; Yan S; Wu J; Zhang M; Zheng S
    PLoS One; 2016; 11(5):e0155179. PubMed ID: 27171501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation.
    Salcedo M; Rodríguez-Mahou M; Rodríguez-Sainz C; Rincón D; Alvarez E; Vicario JL; Catalina MV; Matilla A; Ripoll C; Clemente G; Bañares R
    Liver Transpl; 2009 May; 15(5):530-9. PubMed ID: 19399747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nationwide population-based study reveals increased malignancy risk in taiwanese liver transplant recipients.
    Tsai YF; Chen HP; Liu FC; Liu SH; Chen CY; Cheng CW; Lin JR
    Oncotarget; 2016 Dec; 7(50):83784-83794. PubMed ID: 27626495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.